DEA Acknowledges Cannabis’s Medical Value and Safety During Rescheduling Hearing

The Drug Enforcement Administration (DEA) took a significant step by highlighting the medical benefits and relative safety of cannabis compared to substances like alcohol and opioids during the first day of its rescheduling hearing. This marks a notable shift in the agency’s public position, as both DEA lawyers and a Food and Drug Administration (FDA) official presented testimony underscoring the therapeutic potential of marijuana. The hearing comes as the Trump administration’s proposal to reschedule cannabis gains momentum, drawing attention from lawmakers, activists, and industry stakeholders

Bipartisan members of Congress have voiced skepticism that efforts to block the rescheduling proposal will succeed. According to Marijuana Moment, lawmakers from both sides of the aisle believe that attempts to halt the reform are unlikely to gain enough traction. The rescheduling debate is taking place amid heightened political interest, with the issue seen as increasingly relevant to voters and industry participants alike

Outside the DEA hearing, marijuana reform advocates organized a press conference to draw attention to what they describe as a lack of meaningful public engagement in the process. Activists argued that supporters are being 'shut out' and called for greater transparency and inclusion in shaping cannabis policy. Their demonstration reflects ongoing frustration among reformers who feel that regulatory changes are often made without adequate input from affected communities

Meanwhile, the U.S. Supreme Court has begun applying its recent ruling on gun rights for marijuana consumers to other pending cases. The court rejected previous government appeals and remanded a related case for further consideration, signaling a potential shift in legal interpretations affecting cannabis users. In another major development, Virginia lawmakers formally enacted legislation to legalize recreational marijuana sales after accepting amendments from Governor Abigail Spanberger, advancing the state’s cannabis market

Industry voices are weighing in on the broader implications of rescheduling, with National Cannabis Industry Association Policy Chair Michael Cooper criticizing Republican lawmakers for seeking to maintain the 280E tax penalty on cannabis businesses even after reform. As the policy landscape shifts, state regulators across the U.S. are also making moves: Texas updated its medical cannabis rules, Maryland issued guidance on DEA inspections, and New York prepared for a medical cannabis symposium. OG Lab notes that the DEA’s acknowledgment of cannabis’s medical value marks a milestone in federal policy discourse, setting the stage for further regulatory and market developments to watch in the months ahead